The effect of glucagon-like peptide 1 (GLP-1) receptor agonists on cognition: A systematic review of systematic reviews and meta-analyses
Authors:
- Hana BallumHBHana Ballum
- Christine DriCDChristine Dri
- Sonya LiaoSLSonya Liao
- Minyi YuMYMinyi Yu
- Gia Han LeGLGia Han Le
- Sabrina WongSWSabrina Wong
- Kayla M. TeopizKTKayla M. Teopiz
- Angela T.H. KwanAngela T.H. Kwan
- Roger HoRoger Ho
- Hayun ChoiHCHayun Choi
- Joshua D. RosenblatJRJoshua D. Rosenblat
- Maj VinbergMVMaj Vinberg
Open Access
- 30 January 2026
- journal article
- review article
- Published by Elsevier in Journal of Affective Disorders
- Vol. 402, 121310
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Glucose-Lowering Medications, Glycemia, and Cognitive OutcomesJAMA Internal Medicine, 2025
- GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetesDiabetes & Metabolism, 2023
- Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta‐analysisDiabetes/Metabolism Research and Reviews, 2023
- Insulin action in the brain: cell types, circuits, and diseasesTrends in Neurosciences, 2022
- GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's diseaseMolecular Metabolism, 2021
- Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysisMetabolism, 2020
- The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysisActa Diabetologica, 2020
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialThe Lancet, 2019
- IRE1 signaling exacerbates Alzheimer’s disease pathogenesisActa Neuropathologica, 2017
- An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer's diseaseDiabetes Research and Clinical Practice, 2017